Claims for Patent: 11,117,902

Summary for Patent: 11,117,902

Title:	Selective estrogen receptor degraders
Abstract:	Novel selective estrogen receptor degraders (SERDs) according to the formula:pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
Inventor(s):	Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall, Jennifer Anne McMahon
Assignee:	Eli Lilly and Co
Application Number:	US16/876,819
Patent Claims:	1. A crystalline form of the compound of the formula: wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, or a pharmaceutically acceptable salt thereof. 2. A crystalline form according to claim 1, wherein the compound is pharmaceutically acceptable salt thereof. 3. A crystalline form according to claim 2, characterized by having an X-ray powder diffraction (XRPD) pattern comprising peaks at ° 2θ values of 19.8±0.2, in combination with one or more of the peaks selected from the group consisting of 6.8±0.2, 16.0±0.2, and 22.1±0.2. 4. A crystalline form according to claim 2, characterized by having an X-ray powder diffraction (XRPD) pattern comprising peaks at ° 2θ values of Angle Relative Intensity (% of Peak (°2-Theta) +/− 0.2° most intense peak) 1 6.8 29.40 2 15.3 8.30 3 16.0 20.10 4 17.4 7.60 5 18.1 16.00 6 19.8 100.00 7 21.1 14.60 8 22.1 28.90 9 24.9 16.40 10 25.4 21.90. 5. A crystalline form according to claim 2, wherein the pharmaceutically acceptable salt is a benzenesulfonic acid salt. 6. A crystalline form according to claim 5, characterized by having an X-ray powder diffraction (XRPD) pattern comprising peaks at ° 2θ values of wherein the compound is 20.5±0.2 in combination with one or more of the peaks selected from the group consisting of 12.3±0.2, 22.2±0.2, and 23.1±0.2. 7. A crystalline form according to claim 5, characterized by having an X-ray powder diffraction (XRPD) pattern comprising peaks at ° 2θ values of Angle Relative Intensity (°2-Theta) +/− (% of most intense Peak 0.2° peak) 1 7.6 27.10 2 10.6 34.50 3 12.3 42.10 4 12.6 32.30 5 17.7 32.80 6 19.2 26.70 7 20.5 100.00 8 22.2 45.50 9 23.1 36.30 10 24.2 29.80. 8. A crystalline form according to claim 2, wherein the pharmaceutically acceptable salt is a 4-methylbenzenesulfonic acid salt. 9. A crystalline form according to claim 8, characterized by having an X-ray powder diffraction (XRPD) pattern comprising peaks at ° 2θ values of wherein the compound is 20.1±0.2 in combination with one or more of the peaks selected from the group consisting of 12.8±0.2, 19.5±0.2, and 22.8±0.2. 10. A crystalline form according to claim 8, characterized by having an X-ray powder diffraction (XRPD) pattern comprising peaks at ° 2θ values of Angle Relative Intensity (% Peak (°2-Theta) +/− 0.2° of most intense peak) 1 7.6 25.70 2 12.4 27.90 3 12.8 36.80 4 18.9 26.50 5 19.5 56.90 6 20.1 100.00 7 20.9 41.50 8 21.8 40.90 9 22.8 39.40 10 25.4 29.70. 11. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1 in combination with a pharmaceutically acceptable excipient, carrier, or diluent. 12. The pharmaceutical composition according to claim 11, comprising one or more other therapeutic agents. 13. A method of treating breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, gastric cancer, or lung cancer, comprising administering to a patient in need of such treatment an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 1. 14. The method according to claim 13, wherein the breast cancer is ER-positive breast cancer. 15. The method according to claim 13, wherein the gastric cancer is ER-positive gastric cancer. 16. The method according to claim 13, wherein the lung cancer is ER-positive lung cancer.